PPARG and neoplasm: Pioglitazone, both the PPARα and PPARγ agonistic component, inhibit carcinogenesis, tumor progression, proliferative capacity of metastasis-initiating stem cells, migration, invasion and remodel the extracellular matrix and angiogenesis (3, 77, 81).